Is Precision Medicine fulfilling its promise?
“On. September ESMO Daily Reporter interviewed Dr. Rodrigo Dienstmann (Oncoclinicas Precision Medicine, Sao Paulo, Brazil and Vall d’Hebron Institute of Oncology, Barcelona, Spain) who expressed skepticism of whether genetic profiling is capable of guiding cancer therapy in daily clinical practice. Dientmann said: for most tumor types, at the individual patient level, we should calibrate the expectations given the rarity of actionable genetic alterations that have proven clinical impact”. On the 17. October a Symposia named “Precision medicine: Hopes and hypes” on this topic is to be held. 2cureX will follow the symposium, and provide a News update at this page.